SignalX

Seegene FY 2025 Annual Report
Beta

Filed: March 19, 2026· period ending December 31, 2025DART
Seegene Overview

Seegene annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

Seegene FY 2025 Annual Report Analysis

Business Overview

  • • Fiscal year 2025 total sales KRW 474.2B, with exports accounting for 93% of revenue
  • • New diagnostic reagent STARprep™ EZ Buffer launched 2025, reducing total test time by over 50% via no nucleic acid extraction

Risk Factors

  • • No specific quantified foreign exchange risk sensitivity disclosed for FY2025
  • • No new derivative contracts or put-back option agreements added in FY2025 filing

Seegene FY 2025 Key Financial Metrics
DART

Total Assets

KRW 1.24T

▲ +1.6% YoY

Operating Cash Flow

KRW 149.3B

▲ +74.9% YoY

CapEx

KRW 37.4B

▼ -6.6% YoY

Source: KIFRS consolidated financial data from Seegene annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding